Sudden Cardiac Death in Brugada Syndrome.
Publication/Presentation Date
1-1-2020
Abstract
The Brugada syndrome is an inherited channelopathy that alters the main transmembrane ion currents that constitute the cardiac action potential. These changes not only modify the resting electrocardiogram but also predispose patients to develop malignant ventricular tachyarrhythmias that can lead to syncope, cardiac arrest, and sudden cardiac death. This syndrome is responsible for nearly 20% of all sudden cardiac deaths in patients with structurally normal hearts and up to 12% of all sudden cardiac deaths. Brugada syndrome is diagnosed by its characteristic electrocardiogram consisting of a coved-type ST-segment elevation of at least 2 mm followed by a negative T wave in either one of the right precordial leads. These changes can be observed spontaneously or after administration of a sodium channel blocker. While our understanding of this disease has increased tremendously since its first description in 1992, the primary therapeutic option remains implantation of an implantable cardioverter-defibrillator to avoid sudden cardiac death. Therefore, tremendous effort is being made to effectively risk stratify patients to determine who would benefit from implantable cardioverter-defibrillator implantation.
Volume
28
Issue
4
First Page
203
Last Page
207
ISSN
1538-4683
Published In/Presented At
Kabra, N., Gupta, R., Aronow, W. S., & Frishman, W. H. (2020). Sudden Cardiac Death in Brugada Syndrome. Cardiology in review, 28(4), 203–207. https://doi.org/10.1097/CRD.0000000000000259
Disciplines
Medicine and Health Sciences
PubMedID
31008774
Department(s)
Department of Medicine, Cardiology Division, Fellows and Residents
Document Type
Article